Solid tumours: early personalised RNA vaccine research

Personalised RNA vaccines after pancreatic cancer surgery have early research evidence. Distinguish immune responses from proven treatment benefit.

Phase I study

On this page

1.Population and background
2.What the evidence shows
3.Conclusions that cannot be drawn
4.Questions to ask your doctor

Population and background

A post-operative pancreatic cancer study population receiving a personalised RNA neoantigen vaccine and combination treatment within the study.

What the evidence shows

The study observed vaccine-associated T-cell responses and explored their relationship with follow-up outcomes.

Conclusions that cannot be drawn

The small sample cannot guarantee benefit in routine care. This research product cannot be equated with other vaccine projects in Hainan Boao Lecheng, and their data cannot be transferred directly between products.

Questions to ask your doctor

Is a vaccine study matching my condition still recruiting? Which product and combination treatment are used, and how are manufacturing waits, study risks and follow-up arranged?

Related technologies and evidence

Pancreatic cancer · Melanoma · Lung cancer · Liver cancer · Breast cancer

Check research eligibility for each project

Personalised mRNA cancer vaccine

Attempts to train the immune system to recognise individual tumour neoantigens. These must not be confused with vaccines preventing infections.

Sources (2)

Phase I study of personalised RNA neoantigen vaccination for pancreatic cancer ↗ (opens in a new window)Nature · 2023
Cancer Treatment Vaccines ↗ (opens in a new window)National Cancer Institute

View details

Related cancer types and preparation for care

Pancreatic cancer →Record preparation and the care process →

Sources and scope of interpretation

The following sources support the disease information or explanations of evidence on this page. Access and actual patient acceptance requirements must be checked separately for each region. The information checking date does not indicate review by an external medical expert.

Phase I study of personalised RNA neoantigen vaccination for pancreatic cancer ↗ (opens in a new window)Nature · 2023

Tell us what help you need

Ask about the costs and arrangements for cancer care. SinoCareHub helps organise records, contact hospitals and follow up on arrangements. The receiving hospital and doctors determine the diagnosis and treatment plan.

Describe your needs in the initial consultation. The team will help organise medical records in subsequent communication.